Chapman Paul B
Clinical Immunology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Curr Opin Investig Drugs. 2003 Jun;4(6):710-5.
GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an attractive vaccine target but is poorly immunogenic. Our group has pursued several strategies designed to immunize patients against GD3 including using BEC2, an anti-idiotypic monoclonal antibody that mimics GD3. Pilot trials in melanoma and SCLC indicate that BEC2 can induce an anti-GD3 antibody response in a subset of patients and also suggests that immunization with BEC2 is associated with improved survival. A phase III trial is underway in SCLC patients to determine the effects of BEC2 on overall survival.
GD3是一种在神经外胚层来源的肿瘤（如黑色素瘤和小细胞肺癌（SCLC））上表达的神经节苷脂，是一个有吸引力的疫苗靶点，但免疫原性较差。我们团队采用了多种旨在使患者对GD3产生免疫的策略，包括使用BEC2，一种模拟GD3的抗独特型单克隆抗体。黑色素瘤和SCLC的试点试验表明，BEC2可在一部分患者中诱导抗GD3抗体反应，也表明用BEC2免疫与生存期改善相关。一项针对SCLC患者的III期试验正在进行，以确定BEC2对总生存期的影响。
